Cannabis for inflammatory bowel disease: animal models are promising but human trials have not shown efficacy

Animal models show cannabinoids can improve intestinal inflammation, but randomized controlled trials in IBD patients have not demonstrated efficacy for reducing inflammatory disease activity. Cannabis may help with symptom management.

Picardo, Sherman et al.·Therapeutic advances in gastroenterology·2019·Moderate EvidenceReview
RTHC-02229ReviewModerate Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

In animal models, cannabinoids improved intestinal inflammation through the endocannabinoid system. However, the few randomized controlled trials of cannabis or CBD in IBD patients failed to show efficacy for modifying inflammatory disease activity. Cannabis may still be effective for symptomatic management (pain, appetite, nausea).

Key Numbers

Animal models showed improvement in experimental IBD. Few RCTs conducted; none demonstrated efficacy for inflammatory disease activity.

How They Did This

Narrative review of preclinical and clinical data on cannabis and cannabinoids in IBD management.

Why This Research Matters

Many IBD patients use cannabis for symptom relief, and cultural acceptance is growing. Clinicians need to understand the gap between promising animal data and disappointing human trial results.

The Bigger Picture

IBD patients are among the most common self-medicators with cannabis. This review highlights that while cannabis may help patients feel better symptomatically, it does not appear to be addressing the underlying inflammation.

What This Study Doesn't Tell Us

Narrative review. Very few RCTs exist to draw from. The distinction between symptomatic relief and disease modification is critical but hard to study.

Questions This Raises

  • ?Could specific cannabinoid formulations or delivery methods prove more effective?
  • ?Is there a role for cannabis as adjunctive therapy alongside standard IBD treatments?
  • ?Does symptomatic improvement without inflammatory control pose long-term risks?

Trust & Context

Key Stat:
RCTs have not shown cannabis reduces IBD inflammation
Evidence Grade:
Moderate: narrative review integrating animal and human data, limited by the small number of existing RCTs.
Study Age:
Published in 2019.
Original Title:
Insights into the role of cannabis in the management of inflammatory bowel disease.
Published In:
Therapeutic advances in gastroenterology, 12, 1756284819870977 (2019)
Database ID:
RTHC-02229

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Does cannabis help with Crohn's or ulcerative colitis?

It may help with symptoms like pain, nausea, and appetite, but clinical trials have not shown it reduces the underlying intestinal inflammation that defines these diseases.

Should IBD patients stop using cannabis?

This review does not make treatment recommendations. It notes that cannabis may provide symptomatic relief even if it doesn't modify disease activity, and that physicians should be aware of its limitations.

Read More on RethinkTHC

Cite This Study

RTHC-02229·https://rethinkthc.com/research/RTHC-02229

APA

Picardo, Sherman; Kaplan, Gilaad G; Sharkey, Keith A; Seow, Cynthia H. (2019). Insights into the role of cannabis in the management of inflammatory bowel disease.. Therapeutic advances in gastroenterology, 12, 1756284819870977. https://doi.org/10.1177/1756284819870977

MLA

Picardo, Sherman, et al. "Insights into the role of cannabis in the management of inflammatory bowel disease.." Therapeutic advances in gastroenterology, 2019. https://doi.org/10.1177/1756284819870977

RethinkTHC

RethinkTHC Research Database. "Insights into the role of cannabis in the management of infl..." RTHC-02229. Retrieved from https://rethinkthc.com/research/picardo-2019-insights-into-the-role

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.